Rabbit anti Human CDKN2A antibody recognizes human cyclin-dependent kinase inhibitor 2A (CDKN2A), a 16 kDa protein belonging to the CDKN2 cyclin dependent kinase inhibitor family.
CDKN2A acts as a negative regulator of cell proliferation by interacting strongly with CDK4 and CDK6, thus inhibiting their ability to interact with cyclin D and to phosphorylate the retinoblastoma protein.
CDKN2A is an important tumour suppressor and defects in its production results in tumour formation in a wide range of tissues, including cutaneous malignant melanoma and Li-Fraumeni syndrome.
- Target Species
- Species Cross-Reactivity
|Target Species||Cross Reactivity|
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Antiserum Preparation
- Antiserum to human CDKN2A was raised by repeated immunisation of rabbits with highly purified antigen. Purified IgG was prepared from whole serum by affinity chromatography.
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.02% Sodium Azide (NaN3)
- A 19 amino acid peptide located near the amino terminus of human CDKN2A.
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 12 months from date of despatch
- Entrez Gene
- GO Terms
cell cycle checkpoint
G1 phase of mitotic cell cycle
G1/S transition of mitotic cell cycle
negative regulation of cell-matrix adhesion
cyclin-dependent protein kinase inhibitor activity
induction of apoptosis
cell cycle arrest
Ras protein signal transduction
negative regulation of cell proliferation
protein kinase binding
negative regulation of cell growth
negative regulation of NF-kappaB transcription factor activity
positive regulation of smooth muscle cell apoptosis
negative regulation of cyclin-dependent protein kinase activity
positive regulation of macrophage apoptosis
DNA fragmentation involved in apoptotic nuclear change
negative regulation of protein kinase activity
activation of caspase activity
apoptotic mitochondrial changes
regulation of G2/M transition of mitotic cell cycle
transcription activator activity
negative regulation of B cell proliferation
negative regulation of immature T cell proliferation in thymus
positive regulation of DNA damage response, signal transduction by p53 class mediator
positive regulation of transcription from RNA polymerase II promoter
regulation of protein export from nucleus
somatic stem cell division
negative regulation of ubiquitin-protein ligase activity
ubiquitin-protein ligase inhibitor activity
protein K63-linked ubiquitination
positive regulation of cell cycle arrest
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of CDKN2A antibody
|Immunohistology - Paraffin 1
- 1This product requires antigen retrieval using heat treatment prior to staining of paraffin sections. Sodium citrate buffer pH 6.0 is recommended for this purpose.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Western Blotting
- AHP1488 detects a band of approximately 20 kDa in mouse colon cell lysates.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Useful Reagents Available
Product Specific References
Stone, S. et al. (1995) Complex structure and regulation of the P16 (MTS1) locus.
Cancer Res. 55 (14): 2988-94.
Kamb, A. et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
Nat Genet. 8 (1): 23-6.
Kratzke, R.A. et al. (1995) Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma.
J Natl Cancer Inst. 87 (24): 1870-5.
Stott, F.J. et al. (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
EMBO J. 17 (17): 5001-14.